5/9
04:24 pm
inmb
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update [Yahoo! Finance]
Medium
Report
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update [Yahoo! Finance]
5/9
04:05 pm
inmb
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update
Medium
Report
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update
5/7
08:00 am
inmb
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
Low
Report
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
4/30
08:17 am
inmb
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years [Yahoo! Finance]
Low
Report
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years [Yahoo! Finance]
4/30
08:00 am
inmb
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
Medium
Report
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
4/29
08:10 am
inmb
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer [Yahoo! Finance]
Low
Report
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer [Yahoo! Finance]
4/29
08:00 am
inmb
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Medium
Report
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
4/26
06:45 am
inmb
INmune Bio Independent Director Acquires 80% More Stock [Yahoo! Finance]
Low
Report
INmune Bio Independent Director Acquires 80% More Stock [Yahoo! Finance]
4/25
09:19 am
inmb
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]
Low
Report
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]
4/25
09:00 am
inmb
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Low
Report
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4/23
08:12 am
inmb
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay [Yahoo! Finance]
Medium
Report
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay [Yahoo! Finance]
4/23
08:00 am
inmb
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
Medium
Report
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
4/22
08:13 am
inmb
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering [Yahoo! Finance]
High
Report
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering [Yahoo! Finance]
4/22
08:00 am
inmb
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
High
Report
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
4/22
05:02 am
inmb
INmune Bio: An Opportunity In The Freefall (Rating Upgrade) [Seeking Alpha]
High
Report
INmune Bio: An Opportunity In The Freefall (Rating Upgrade) [Seeking Alpha]
4/8
08:14 am
inmb
INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 [Yahoo! Finance]
Medium
Report
INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 [Yahoo! Finance]
4/8
08:00 am
inmb
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
Medium
Report
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
4/1
10:25 am
inmb
INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/28
04:19 pm
inmb
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update [Yahoo! Finance]
Medium
Report
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update [Yahoo! Finance]
3/28
04:01 pm
inmb
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
Medium
Report
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
3/26
04:18 pm
inmb
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28 [Yahoo! Finance]
Low
Report
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28 [Yahoo! Finance]
3/26
04:01 pm
inmb
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
Low
Report
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
3/13
08:12 am
inmb
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy [Yahoo! Finance]
Low
Report
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy [Yahoo! Finance]
3/13
08:00 am
inmb
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
Low
Report
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
3/5
08:10 am
inmb
INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro™ [Yahoo! Finance]
Medium
Report
INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro™ [Yahoo! Finance]